LifeStance Health Group (LFST) closed the last trading session at $6.80, gaining 2.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.75 indicates a 28.7% upside potential.The average comprises eight short-term price targets ranging from a low of $7 to a high of $10, with a standard deviation of $1.07. While the lowest estimate indicates an increase of 2.9% from the current pric ...

Group 1 - The core thesis for LifeStance Health Group (NASDAQ: LFST) is based on the growing demand in the industry, which the company is positioned to capitalize on [1] - The investment approach emphasizes identifying undervalued companies with long-term growth potential, focusing on quality companies purchased at a discount to their intrinsic value [1] Group 2 - The article does not provide any specific financial data or performance metrics related to LifeStance Health Group or the industry [2][3]

Core Viewpoint - LifeStance Health Group, Inc. is set to release its first quarter 2025 earnings on May 7, 2025, before market opening, highlighting its position as a major player in outpatient mental health care [1]. Group 1: Earnings Release Information - LifeStance will host a live earnings conference call on May 7, 2025, at 8:30 a.m. Eastern Time to discuss the first quarter results [2]. - Participants can join the call by dialing specific domestic and international numbers and using a conference ID [2]. - A real-time audio webcast will be available on the LifeStance Investor Relations website, with related materials posted prior to the call [3]. Group 2: Company Overview - Founded in 2017, LifeStance is one of the largest providers of virtual and in-person outpatient mental health care in the U.S. [4]. - The company employs approximately 7,400 mental health professionals and operates over 550 centers across 33 states [4]. - LifeStance aims to improve access to affordable and personalized mental health care, helping individuals lead healthier lives [4].

LifeStance Health Group (LFST) shares soared 5.8% in the last trading session to close at $6.91. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This outpatient mental health services provider is expected to post quarterly loss of $0.03 per share in it ...

Core Viewpoint - LifeStance Health Group (LFST) has experienced a significant downtrend, with a 13.6% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with a reading below 30 indicating oversold conditions [2]. - LFST's current RSI reading is 29.22, suggesting that the heavy selling pressure may be exhausting, indicating a possible price rebound [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding LFST, with earnings estimates for the current year increasing by 29.8% over the last 30 days, which typically correlates with price appreciation [6]. - LFST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [7].

Reimagining Mental Health Q4 2024 Earnings Presentation • February 27, 2025 Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding: full-year and first quarter guidance and ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Monica Prokocki - VP, IR Ken Burdick - CEO David Bourdon - CFO Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JPMorgan Jamie Perse - Goldman Sachs Brian Tanquilut - Jefferies Andrea Alfonso - UBS Operator Thank you for standing by. My name is Danielle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Life ...

Lifestance Health Group (LFST) Q4 2024 Earnings Call February 27, 2025 05:54 PM ET Company Participants Monica Prokocki - Vice President, Investor RelationsKenneth Burdick - ChairmanDavid Bourdon - CEOCraig Hettenbach - Executive DirectorLisa Gill - Managing DirectorAndrea Alfonso - Executive Director Conference Call Participants Jamie Perse - Equity Research AnalystBrian Tanquilut - Equity Research Analyst - Healthcare Services Operator Thank you for standing by. My name is Danielle, and I will be your con ...

Financial Restrictions and Debt Management - The 2024 Credit Agreement imposes significant operating and financial restrictions, including dedicating a portion of cash flows to debt repayment[219]. - The 2024 Credit Agreement includes a financial maintenance covenant requiring compliance with a maximum leverage ratio at the end of each fiscal quarter[221]. - The company may face challenges in raising additional debt or equity financing during economic downturns due to restrictive covenants[225]. - As of December 31, 2024, the company had an aggregate principal amount of $290.0 million outstanding under its credit facilities[355]. Corporate Governance and Control - Principal Stockholders control approximately 57.6% of the common stock, allowing them to influence corporate decisions and the Board of Directors[223]. - The company is classified as a "controlled company," qualifying for exemptions from certain corporate governance requirements, which may limit stockholder protections[225]. - The corporate governance documents may hinder potential acquisitions and attempts by stockholders to replace management[236]. - The exclusive forum provisions in the amended certificate of incorporation may limit stockholders' ability to choose judicial forums for disputes[237]. Internal Controls and Financial Reporting - Material weaknesses in internal control over financial reporting were identified, impacting the accuracy of financial statements and leading to restatements for prior years[230]. - The company has made progress in remediating material weaknesses but must maintain effective internal controls to avoid misstatements and loss of investor confidence[233]. Costs and Compliance - The company may incur increased costs due to compliance with public company responsibilities, including legal and accounting expenses[229]. Market Conditions and Stock Performance - The company's stock price is highly volatile and may fluctuate due to various factors, including changes in operating results and market conditions[243]. - The trading market for the company's shares is influenced by analysts' reports, and downgrades or negative coverage could lead to a decline in share price[248]. - The company acknowledges that market risk exposure is primarily due to potential changes in inflation or interest rates[353]. Interest Rate and Financial Strategy - The company entered into an interest rate swap in August 2022 to hedge its exposure to interest rate risks, aiming to eliminate variability in cash flows related to variable-rate loans[355]. - The company does not expect any increase or decrease in interest rates of 100 basis points to have a material effect on its business or financial condition[356]. Dividends and Shareholder Returns - The company does not currently pay dividends and does not anticipate paying dividends in the foreseeable future, with any future dividends being at the discretion of the Board of Directors[247]. Conflicts of Interest - The company renounces any interest in certain corporate opportunities, which could adversely impact its business[241]. - The company faces potential conflicts of interest from its Principal Stockholders, who may allocate corporate opportunities to themselves instead of the company[242]. Economic Factors - The company believes inflation has not had a material effect on its operating results, but future inflation could adversely impact its financial condition[357].

Group 1 - LifeStance Health Group reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.12 per share a year ago, representing a 50% earnings surprise [1] - The company achieved revenues of $325.48 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 4.03%, and up from $280.6 million year-over-year [2] - LifeStance Health has surpassed consensus EPS estimates for four consecutive quarters, indicating a strong performance trend [2] Group 2 - The stock has gained approximately 1.9% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] - The company's earnings outlook is favorable, with current consensus EPS estimates of -$0.06 on revenues of $339.54 million for the upcoming quarter and -$0.14 on revenues of $1.38 billion for the current fiscal year [7] - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a positive industry outlook [8]